Drug intelligence / Profile preview

MSCP

Development stage: Preclinical
Lead developer: Orgenesis
Modality: Stem Cell Therapies → Cell Therapies

Overview

MSCP is an investigational mesenchymal stem cell (MSC) therapy being developed by Orgenesis, primarily targeting psoriasis and wound healing. As a cell-based therapeutic, MSCP utilizes the regenerative and immunomodulatory properties of mesenchymal stem cells to address inflammatory skin conditions and promote tissue repair. The therapy is designed to modulate the local immune environment and stimulate the healing process through the secretion of various paracrine factors and direct cell-to-cell interactions. Currently in the IND-enabling stage, MSCP represents a component of Orgenesis's broader portfolio of cell-based treatments aimed at metabolic and autoimmune diseases.

Other names: Mesenchymal stem cell productOrgenesis MSCP

Beyond the preview

Go deeper on MSCP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MSCP.

Explore the full profile